Cargando…
11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases
Glucocorticoids (GCs) belong to the group of steroid hormones. Their representative in humans is cortisol. GCs are involved in most physiological processes of the body and play a significant role in important biological processes, including reproduction, growth, immune responses, metabolism, mainten...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605099/ https://www.ncbi.nlm.nih.gov/pubmed/36294507 http://dx.doi.org/10.3390/jcm11206190 |
_version_ | 1784817981492035584 |
---|---|
author | Kupczyk, Daria Studzińska, Renata Kołodziejska, Renata Baumgart, Szymon Modrzejewska, Martyna Woźniak, Alina |
author_facet | Kupczyk, Daria Studzińska, Renata Kołodziejska, Renata Baumgart, Szymon Modrzejewska, Martyna Woźniak, Alina |
author_sort | Kupczyk, Daria |
collection | PubMed |
description | Glucocorticoids (GCs) belong to the group of steroid hormones. Their representative in humans is cortisol. GCs are involved in most physiological processes of the body and play a significant role in important biological processes, including reproduction, growth, immune responses, metabolism, maintenance of water and electrolyte balance, functioning of the central nervous system and the cardiovascular system. The availability of cortisol to the glucocorticoid receptor is locally controlled by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Evidence of changes in intracellular GC metabolism in the pathogenesis of obesity, metabolic syndrome (MetS) and cardiovascular complications highlights the role of selective 11β-HSD1 inhibition in the pharmacotherapy of these diseases. This paper discusses the role of 11β-HSD1 in MetS and its cardiovascular complications and the importance of selective inhibition of 11β-HSD1. |
format | Online Article Text |
id | pubmed-9605099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96050992022-10-27 11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases Kupczyk, Daria Studzińska, Renata Kołodziejska, Renata Baumgart, Szymon Modrzejewska, Martyna Woźniak, Alina J Clin Med Review Glucocorticoids (GCs) belong to the group of steroid hormones. Their representative in humans is cortisol. GCs are involved in most physiological processes of the body and play a significant role in important biological processes, including reproduction, growth, immune responses, metabolism, maintenance of water and electrolyte balance, functioning of the central nervous system and the cardiovascular system. The availability of cortisol to the glucocorticoid receptor is locally controlled by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Evidence of changes in intracellular GC metabolism in the pathogenesis of obesity, metabolic syndrome (MetS) and cardiovascular complications highlights the role of selective 11β-HSD1 inhibition in the pharmacotherapy of these diseases. This paper discusses the role of 11β-HSD1 in MetS and its cardiovascular complications and the importance of selective inhibition of 11β-HSD1. MDPI 2022-10-20 /pmc/articles/PMC9605099/ /pubmed/36294507 http://dx.doi.org/10.3390/jcm11206190 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kupczyk, Daria Studzińska, Renata Kołodziejska, Renata Baumgart, Szymon Modrzejewska, Martyna Woźniak, Alina 11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases |
title | 11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases |
title_full | 11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases |
title_fullStr | 11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases |
title_full_unstemmed | 11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases |
title_short | 11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases |
title_sort | 11β-hydroxysteroid dehydrogenase type 1 as a potential treatment target in cardiovascular diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605099/ https://www.ncbi.nlm.nih.gov/pubmed/36294507 http://dx.doi.org/10.3390/jcm11206190 |
work_keys_str_mv | AT kupczykdaria 11bhydroxysteroiddehydrogenasetype1asapotentialtreatmenttargetincardiovasculardiseases AT studzinskarenata 11bhydroxysteroiddehydrogenasetype1asapotentialtreatmenttargetincardiovasculardiseases AT kołodziejskarenata 11bhydroxysteroiddehydrogenasetype1asapotentialtreatmenttargetincardiovasculardiseases AT baumgartszymon 11bhydroxysteroiddehydrogenasetype1asapotentialtreatmenttargetincardiovasculardiseases AT modrzejewskamartyna 11bhydroxysteroiddehydrogenasetype1asapotentialtreatmenttargetincardiovasculardiseases AT wozniakalina 11bhydroxysteroiddehydrogenasetype1asapotentialtreatmenttargetincardiovasculardiseases |